SEC Form 4 · accession 0001209191-18-000848
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A Rowland Jr.
Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 3, 2018 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $4.48 | Jan 2, 2018 | A | 16,000 | A | Jan 2, 2019 | Jan 2, 2028 | Common Stock | 16,000 | 16,000 | D |